106 In the index

Anamorelin ANAM

A drug tested in large human trials to help cancer patients regain appetite and body weight. It succeeded at helping people gain weight, but it didn't reliably make people physically stronger, and U.S. regulators haven't approved it.

Also known as ONO-7643, DD5RBA1NKF, anamorelina, anamoreline, anamorelinum, RefChem:112510, Anamorelin [INN], RC 1291

Effects Build muscle

Routes Oral

Legal status Unapproved / investigational

WADA Banned at all times

3D Molecular Structure of C₃₁H₄₂N₆O₃

Drag to rotate · scroll to zoom

Chemistry

Formula: C31H42N6O3
Molar mass: 546.7
CAS: 249921-19-5
PubChem CID: 9828911
IUPAC name: 2-amino-N-[(2R)-1-[(3R)-3-benzyl-3-[dimethylamino(methyl)carbamoyl]piperidin-1-yl]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-methylpropanamide
InChIKey: VQPFSIRUEPQQPP-MXBOTTGLSA-N

Reported dosing

Clinical data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 100 mg

Reported range 50-100 mg/day

Route Oral

Frequency Once daily

Duration Chronic, per oncology treatment course

Approved in Japan for cancer-related cachexia (Adlumiz); not broadly approved in the US.

Where this comes from Japanese approval data; Phase III clinical trials (ROMANA studies)

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.